MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT01792518
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 360 participants
- Registry
-
NCT01792518 -
2012-002603-17
-
- Other papers using this trial's data
- Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial
- Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Denmark, Finland, France, Germany, Japan, Philippines, South Korea, Spain, Taiwan, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT01792518. Randomized; double masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2017-03-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Linagliptin 5mg
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01792518- Content hash
418e0e9e4cd662023594874be71f7ac88973efee03bbc5ade6c5c4ffa96c7942